Search

Louisville, Colorado-based GlobeImmune, the biopharmaceuticals developer which is focusing on cancer and infection diseases, has raised $15M in an IPO, and was trading slightly up this morning after its IPO. The company priced at $10 per share last night, well below its initial estimated ofering range of $15.00 to $17.00 per share. GlobeImmune was venture backed by Celgene, HealthCare Ventures, Morgenthaler Partners, Wexford-Kappa Investors, Sequel Ventures, Lilly Ventures, and Medica Venture Partners. The company is now trading as GBIM on the Nasdaq Global Market.
posted on Thursday, July 3, 2014

Related companies:
GlobeImmune

Related stories:
> GlobeImmune Tries Again On IPO
> GlobeImmune Sets IPO Pricing Range
> GlobeImmune Sets Estimated IPO Pricing Range
> GlobeImmune Files For IPO
> GlobeImmune Lands $40M Investment from Celgene

---

Techrockies.com Home